Profile of Adverse Events Following Immunization with Human Papillomavirus and Hepatitis B Vaccines in Females 9 to 26 years in Canada

被引：0
|
作者：
Nkanza, J.
Lafleche, J.
Anyoti, H.
Pless, R.
Law, B.
机构：
来源：
DRUG SAFETY | 2010年 / 33卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
131
引用
收藏
页码：950 / 950
页数：1
相关论文
共 22 条
  • [21] Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial
    Thiem, Vu Dinh
    Quang, Nguyen Dang
    Tuan, Nguyen Hai
    Cheon, Kyeongmi
    Gallagher, Nancy
    Luxembourg, Alain
    Group, Thomas
    Badshah, Cyrus
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (07) : 1980 - 1985
  • [22] Comparison of Post-Licensure Vaccine Adverse Event Reporting System (VAERS) Reports Involving Quadrivalent Human Papillomavirus Vaccine (Gardasil®) and Meningococcal Conjugate Vaccine (Menactra®) in Females Aged 11-26 Years
    Davlin, Stacy
    Rupp, Richard
    Berenson, Abbey
    [J]. JOURNAL OF WOMENS HEALTH, 2014, 23 (04) : 4 - 5
123